

**Glenmark Pharmaceuticals Limited**  
**Statement of unaudited financial results for the quarter ended 30 June, 2018** (Rs.In Millions)

	Particulars [ Refer notes below ]	Standalone (Ind AS)			
		Quarter ended 30/06/2018 (Unaudited)	Quarter ended 31/03/2018 (Audited) [refer note 10]	Quarter ended 30/06/2017 (Unaudited)	Year ended 31/03/2018 (Audited)
I	Revenue from operations				
	(a) Net sales	15,632.28	15,063.27	15,109.26	60,960.52
	(b) Other operating income	551.79	1,614.18	368.52	3,358.32
	Total revenue from operations	16,184.07	16,677.45	15,477.78	64,318.84
II	Other income	1,736.49	442.98	425.88	1,804.22
III	Total income ( I + II )	17,920.56	17,120.43	15,903.66	66,123.06
IV	Expenses				
	(a) Cost of materials consumed	5,147.65	5,312.54	5,000.21	20,385.67
	(b) Purchase of stock-in-trade	746.72	632.69	693.06	2,881.77
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(172.13)	347.33	(109.34)	518.47
	(d) Employee benefits expense	2,296.89	2,323.30	2,077.68	10,219.21
	(e) Finance costs	551.71	507.22	457.37	1,908.98
	(f) Depreciation and amortisation expense	334.17	298.18	299.41	1,182.04
	(g) Other expenses	4,061.97	4,758.48	4,286.75	16,838.67
	Total expenses ( IV )	12,966.98	14,179.74	12,705.14	53,934.81
V	Profit/(loss) before exceptional items and tax ( III - IV )	4,953.58	2,940.69	3,198.52	12,188.25
VI	Exceptional items	-	-	-	-
VII	Profit/(loss) before tax ( V - VI )	4,953.58	2,940.69	3,198.52	12,188.25
VIII	Tax expense :				
	Current tax	1,070.08	733.52	682.31	2,706.77
	Deferred tax	(90.41)	(7.95)	(192.17)	(661.99)
IX	Profit/(loss) for the period ( VII - VIII )	3,973.91	2,215.12	2,708.38	10,143.47
X	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss	25.10	36.41	(8.60)	(10.20)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(8.77)	(12.60)	2.98	3.53
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	Total comprehensive income	3,990.24	2,238.93	2,702.76	10,136.80
XII	Total comprehensive income attributable to:				
	- Non-controlling interests	-	-	-	-
	- Owners of the Company	3,990.24	2,238.93	2,702.76	10,136.80
XIII	Other equity	-	-	-	103,632.24
XIV	Earning per share (EPS)				
	(of Re 1/- each) (not annualised )				
	Basic EPS (in Rupees )	14.08	7.85	9.60	35.95
	Diluted EPS (in Rupees )	14.08	7.85	9.60	35.95



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

